thumbnail_IMG_5960_optimized_600.jpeg

EVA Pharma’s roots stretch back over a hundred years.

thumbnail_Pharmacy.jpeg

Pharmacy.jpeg

Our History

Our experienced leadership team keeps us on track.

thumbnail_Find_Out_More_Leaders.png

Find_Out_More_Leaders.png

Meet our Leaders

EVA Pharma’s success is based on its dynamic team, Our people are our power.

thumbnail_1704997569480.jfif

1704997569480.jfif

Life at EVA Pharma

GOLDEN, Colo., CAIRO, Egypt — October 30, 2025 — <a href="https://pharmajet.com/">PharmaJet</a>®, a company that strives to improve the performance and outcomes of injectables with its enabling needle-free injection technology, today announced that it has signed a Distribution Agreement with <a href="https://atr-eg.com/our-history/">ATR</a>, an affiliate to <a href="https://www.evapharma.com/en">EVA Pharma</a>, the leading pharmaceutical company driving healthcare innovation and access across the Middle East and Africa. The agreement, signed in Frankfurt at the&nbsp;CPHI meeting&nbsp;on October 30, 2025, includes provisions for Tropis distribution, technology transfer, and manufacturing. 
&nbsp;
The aim of the collaboration is to increase needle-free access within Egypt and regionally while broadening Egypt’s manufacturing capabilities. PharmaJet’s <a href="https://pharmajet.com/tropis-id/">Tropis®</a> intradermal needle-free delivery offers several strategic advantages for Egypt including substantial polio immunization cost savings1, reduced vaccine hesitancy2,3, increased coverage3, and the potential for medical technology regional manufacturing. The signing follows the <a href="https://pharmajet.com/pharmajet-enters-into-mou-agreement-with-egyptian-upa-and-eva-pharma-to-provide-needle-free-delivery-for-routine-immunization-in-egypt/">July 2025 Memo of Understanding (MOU)</a> that was signed between PharmaJet, Egypt’s Unified Procurement Agency (UPA) and EVA Pharma, which outlined plans for how UPA could incorporate Tropis into its portfolio. 
&nbsp;
The introduction of Tropis into immunization programs supports Egypt’s&nbsp;“<a href="https://www.egypttoday.com/Article/1/125918/Egypt-set-to-launch-1000-Golden-Days-initiative-to-develop">1000 Golden Days"</a>&nbsp;initiative which was launched to support the health and development of families during the critical period from conception to a child's second birthday. The collaboration will enable total immunization cost reduction and improved acceptability of polio vaccinations. Longer-term, the Tropis manufacturing and other needle-free product development initiatives may expand the benefits to vaccination against other infectious agents and improved pandemic preparedness. 
&nbsp;
EVA Pharma is a leading pharmaceutical and medical appliances manufacturing company that has vast experience in manufacturing, registering, marketing, distributing, and promoting pharmaceutical products. “This collaboration puts children first,” said Riad Armanious, CEO of EVA Pharma. “We’re reimagining vaccination through local innovation that improves every child’s experience while empowering healthcare professionals. By localizing manufacturing, we expand access and use existing budgets to reach many more children in Africa sustainably.” 
&nbsp;
“We are proud to collaborate with ATR and EVA Pharma to localize needle-free manufacturing and delivery,” said Paul LaBarre, Senior Vice President of Business Development for PharmaJet. “This partnership represents a strategic step forward for PharmaJet in the Middle East and Northern Africa region. Working with these innovative teams will accelerate integration of needle-free intradermal vaccine delivery into routine immunization programs in Egypt and beyond.” 
&nbsp;
Refer to Instructions for Use to ensure safe injections and to review risks.&nbsp;
&nbsp;
1 Data on file
2 Soonawala, D et al, <a href="https://www.sciencedirect.com/science/article/abs/pii/S0264410X13007640?via%3Dihub">Intradermal fractional booster dose of inactivated poliomyelitis vaccine with a jet injector in healthy adults,</a> Vaccine, Volume 31, Issue 36,&nbsp;12 August 2013, Pages 3688-3694
3 Mohan, D et al, <a href="https://www.mdpi.com/2076-393X/13/5/533">Evaluating the impact of needle-free delivery of inactivated polio vaccine on Nigeria’s routine immunization program: An implementation hybrid trial</a> , Vaccines,16 May 2025, 13(5), p.533
&nbsp;
&nbsp;
About PharmaJet
The PharmaJet mission is to improve the performance and outcomes of injectables with our enabling technology that better activates the immune system. We are committed to helping our partners realize their research and commercialization goals while making an impact on public health. PharmaJet Precision Delivery Systems™ can improve vaccine effectiveness, allow for a preferred patient and caregiver experience, and offer a proven path to commercialization. They are also safe, fast, and easy-to-use. <a href="https://pharmajet.com/tropis-id/">Tropis® &nbsp;ID</a> has CE Mark and WHO PQS certification for intradermal injections and is commercially available for global immunization programs. For more information or if you are interested in partnering with PharmaJet visit <a href="https://www.pharmajet.com/">https://www.pharmajet.com</a> or contact PharmaJet <a href="https://pharmajet.com/contact/">here</a>. Follow us on <a href="https://www.linkedin.com/company/pharmajet-inc/">LinkedIn</a>.
&nbsp;
&nbsp;
About EVA Pharma&nbsp;
EVA Pharma is dedicated to improving access to affordable, high-quality medicines around the world, focusing on three core pillars: innovation, development and sustainable access. The company leverages cutting-edge technology at two research centers bringing first-of-its-kind capabilities to the Middle East and Africa including mRNA research and development from AI prediction to biologic products.&nbsp;With a 5,000-strong team of professionals, EVA Pharma produces more than one million healthcare products a day at four state-of-the-art manufacturing facilities, which are internationally recognized for innovation, and have been approved by multiple regulatory agencies.&nbsp;Guided by a relentless drive to ensure sustainable access to pressing yet unmet disease areas, the company’s product portfolio focuses on twelve therapeutic areas: Anti-infectives, metabolic health, bone, neuroscience, oncology, respiratory, gynecology, urology and andrology, pediatrics, ophthalmology, gastrointestinal tract, family medicine to meet both local and international demand.&nbsp;EVA Pharma is one of the fastest-growing healthcare companies in the Middle East and Africa, with an extensive pan-African presence, while operating in more than 70 countries worldwide.&nbsp;For more information, please visit: <a href="https://www.evapharma.com/en">https://www.evapharma.com/en</a>.
&nbsp;

Press Release

PharmaJet® Signs Distribution Agreement with EVA Pharma to Provide Needle-free Injection Systems to Support Routine Polio Immunization in Egypt

PharmaJet® Signs Distribution Agreement with EVA Pharma to Provide Needle-free Injection Systems to Support Routine Polio Immunization in Egypt

29 Oct, 2025

PharmaJet® Signs Distribution Agreement with EVA Pharma to Provide Needle-free Injection Systems to Support Routine Polio Immunization in Egypt

29 Oct, 2025

Find out more about EVA Pharma

EVA Pharma’s roots stretch back over a hundred years.

Our experienced leadership team keeps us on track.

EVA Pharma’s success is based on its dynamic team, Our people are our power.

© 2026 Eva Pharma All Rights Reserved - شركة ايفا فارما للادوية و المستلزمات الطبية